Anhui Fengyuan Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary Bengbu Fengyuan Tushan Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for vonoprazan fumarate tablets issued by the National Medical Products Administration. The approved strengths are 10 mg and 20 mg, both classified as Category 4 chemical drugs, and the drug approval number is valid until August 24, 2031. Vonoprazan fumarate is a potassium-competitive acid blocker used to treat reflux esophagitis and Helicobacter pylori infection. The company stated that this approval will enrich its product line, optimize its product structure, and enhance market competitiveness, but drug production and sales are subject to industry policies and market conditions, and uncertainties remain.
Anhui Fengyuan Pharmaceutical Co LtdWholly-owned subsidiary received NMPA Drug Registration Certificate for vonoprazan fumarate tablets, expanding its product line.
The subsidiary itself obtained the NMPA Drug Registration Certificate for vonoprazan fumarate tablets.
